Cerebral Folate Deficiency Syndrome: Early Diagnosis, Intervention and Treatment Strategies

Vincent Th Ramaekers1, Edward V Quadros2

  • 1Autism Reference Center, University of Liege, 4000 Liege, Belgium.

Nutrients
|August 12, 2022
PubMed

Insights

Cerebral folate deficiency syndrome (CFDS) involves low brain folate levels causing neurological issues. Autoimmunity against folate receptor-alpha (FRα) is the main cause, impacting folate transport to the brain.

Area of Science:

  • Neuroscience
  • Pediatric Neurology
  • Immunology

Background:

  • Cerebral folate deficiency syndrome (CFDS) presents as neuropsychiatric or developmental disorders with low cerebrospinal fluid (CSF) folate.
  • Normal systemic folate levels contrast with central nervous system folate depletion in CFDS.
  • Clinical presentation varies based on intrauterine folate status and age of onset.

Purpose of the Study:

  • To review folate receptor-alpha (FRα) autoimmunity in CFDS.
  • To detail age-dependent clinical syndromes, diagnostic criteria, and treatment strategies for CFDS.
  • To discuss prevention in at-risk populations.

Main Methods:

  • Focus on FRα autoimmunity as the primary etiology of CFDS.
  • Review of diagnostic criteria for CFDS.
  • Discussion of treatment and prevention strategies.

Main Results:

  • Serum FRα autoantibodies are the predominant cause of CFDS, inhibiting folate transport across the choroid plexus.
  • Other causes include mitochondrial disorders, inborn errors of metabolism, and FOLR1 gene mutations.
  • Early diagnosis and intervention are crucial for improved outcomes in CFDS.

Conclusions:

  • FRα autoimmunity is the key mechanism underlying most CFDS cases.
  • Understanding age-dependent presentations is vital for accurate diagnosis.
  • Timely management, including potential prevention strategies, can significantly improve prognosis.

Related Concept Videos

Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
171
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
254
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
216